IFN Regulatory Factor 8 Represses GM-CSF Expression in T Cells To Affect Myeloid Cell Lineage Differentiation

Amy V. Paschall, Ruihua Zhang, Chen-Feng Qi, Kankana Bardhan, Liang Peng, Geming Lu, Jianjun Yang, Miriam Merad, Tracy McGaha, Gang Zhou, Andrew Mellor, Scott I. Abrams, Herbert C. Morse III, Keiko Ozato, Huabao Xiong and Kebin Liu

*J Immunol* published online 2 February 2015
http://www.jimmunol.org/content/early/2015/01/31/jimmunol.1402412
Adaptive immune component of the immune system regulates the innate immune cell myelopoiesis in vivo. To repress GM-CSF expression in T cells to control myeloid cell lineage differentiation, revealing a novel mechanism that the IRF8-deficient T cells exhibit abnormal myeloid cell lineage differentiation. Instead, mice with IRF8 deficiency only in T cells exhibit deregulated myeloid cell differentiation and MDSC accumulation. Our data determine that, in addition to its intrinsic function as an apoptosis regulator in myeloid cells, IRF8 also acts extrinsically to control myeloid cell lineage differentiation, revealing a novel mechanism that the adaptive immune component of the immune system regulates the innate immune cell myelopoiesis in vivo.

Myeloid cells are among the most abundant and heterogeneous hematopoietic cell types that are virtually present in all mammalian tissues, where they monitor local microenvironment to maintain homeostasis (1–4). All myeloid cells originate from the pluripotent hematopoietic stem cells that undergo progressive restriction in their lineage potential to give rise to mature granulocytes and macrophages (5–8). Lineage restriction and differentiation are regulated by timely activation of specific set(s) of transcription factors that are important for alternative cell lineage potential (9, 10). Deregulation of activities of these lineage-specific transcription factors often leads to hematopoietic disorders and leukemia (11, 12). Therefore, lineage-specific transcription factors are essential for myeloid cell lineage differentiation and maturation (11, 13–15).

Several lineage-specific transcription factors have been found to be essential for regulation of myeloid cell differentiation. The E-twenty-six (ETS) family transcription factor PU.1 is necessary for the earliest steps of myeloid lineage commitment, and its deficiency results in loss of monocytes and granulocytes (16–18). Krüppel-like factor-4 (KLF4) is expressed in a monocyte-restricted and lineage-specific pattern during myelopoiesis and functions to promote monocyte differentiation (19). KLF4 deficiency inhibited monocyte, but increased granulocyte differentiation (20). Furthermore, hematopoietic KLF4−/− chimeras generated by transplantation of KLF4−/− fetal liver cells completely lack circulating inflammatory Ly6G+ monocytes (21). In contrast, the nuclear orphan receptor NR4A1 controls later stages of monocyte development, and is required for the generation of Ly6C− monocytes, but not Ly6C+ monocytes (22). The bZIP transcription factor MafB is expressed specifically in the myeloid lineage of the hematopoietic system and is upregulated successively during myeloid
differentiation from multipotent progenitors to macrophages, and thus plays an essential role in early myeloid and monocytic differentiation (23). c-Maf has been observed to induce monocytic differentiation in bipotent myeloid progenitors (24), whereas the zinc finger transcription factor Egr-1 is essential for lineage differentiation of macrophages, but not granulocytes (25).

IFN regulatory factor (IRF)8 is a member of the IRF family that was identified in the late 1980s in the context of research into the type 1 IFN system. Subsequent studies over the past three decades have revealed that IRF8 is an essential transcription factor for myeloid-lineage restriction and differentiation (6–8, 26–31). IRF8 functions as either a transcriptional activator or repressor, depending on its binding partners in which it forms different heterodimeric protein complexes and on its target DNA elements (10, 19, 32). For example, IRF8 forms a protein complex with IRF1 or IRF2 and binds to the IFN-stimulated response element (A/GNAANNNGAAA) to repress gene transcription. Conversely, the IRF8-PU.1 heterodimer complex specifically binds to the ETS-IRF composite element (GGAANNGAAA) or the IRF-ETS composite sequence (GAAN[NJ]GGAA) to activate gene transcription (19, 27, 33, 34). In humans, a loss-of-function mutation of IRF8 leads to monocytic and dendritic cell immunodeficiency (35). A hallmark of IRF8 null mice is deregulated myeloid cell lineage differentiation, as characterized by lack of myeloid cell maturation, including lack of bone marrow (BM) resident macrophages, CD8α+ dendritic cells, and plasmacytoid dendritic cells in lymphoid organs (36, 37). This deregulated myeloid cell differentiation causes massive accumulation of heterogeneous CD11b+Gr1+ myeloid cells that phenotypically and functionally resemble myeloid-derived suppressor cells (MDSCs) (38). Therefore, IRF8 is essential for the regulation of diverse stages of myelopoiesis, namely the differentiation and lineage commitment of monocytes/macrophages versus granulocytes under physiological conditions (36, 37). However, the mechanism underlying IRF8 function in myeloid cell differentiation and MDSC accumulation is still elusive. Furthermore, IRF8 is expressed in both lymphoid and myeloid cells, but little is known about its relative functions in lymphoid and myeloid cells in regulation of myeloid cell differentiation and MDSC accumulation.

We report in this work a surprising finding that IRF8 expressed in myeloid cells regulates myeloid cell spontaneous apoptosis, whereas IRF8 expressed in T cells represses GM-CSF expression to suppress MDSC differentiation from myeloid progenitor cells. We proposed that IRF8 deficiency in T cells leads to increased GM-CSF expression to induce MDSC differentiation, whereas IRF8 deficiency in myeloid cells leads to decreased myeloid cell spontaneous apoptosis. Thus, cooperative IRF8 functions in T cells and myeloid cells mediate myeloid cell differentiation and homeostasis in vivo.

Materials and Methods

Mice

IRF8 knockout (KO) mice were generated as previously described (36). The IRF8 T KO mice were generated as previously described (39). The loxp-flanked iRf8 gene [B6(Cg)-Irf8tm1.1Hm/J] were generated as previously described (40). The Lyz2-cre mice [B6.129P2-Lyz2tm1(cre)Ifom/J] were obtained from The Jackson Laboratory. Use of mice was performed according to approved protocols by institutional animal use and care committee in Icahn School of Medicine at Mount Sinai and Georgia Regents University.

Antibodies

The following Abs were purchased from BD Biosciences, BioLegend (San Diego, CA), or eBiosciences, as conjugated to FITC, PE, PE-Cy5, and Alexa Fluor 647, as indicated in the figure.

Materials and Methods

Mice

IRF8 knockout (KO) mice were generated as previously described (36). The IRF8 T KO mice were generated as previously described (39). The loxp-flanked iRf8 gene [B6(Cg)-Irf8tm1.1Hm/J] were generated as previously described (40). The Lyz2-cre mice [B6.129P2-Lyz2tm1(cre)Ifom/J] were obtained from The Jackson Laboratory. Use of mice was performed according to approved protocols by institutional animal use and care committee in Icahn School of Medicine at Mount Sinai and Georgia Regents University.

Antibodies

The following Abs were purchased from BD Biosciences, BioLegend (San Diego, CA), or eBiosciences, as conjugated to FITC, PE, PE-Cy5, and Alexa Fluor 647, as indicated in the figure.
PerCP-Cy5.5, or allophycocyanin: CD4 (L3T4), CD8 (53-6.7), CD3e (145-2C11), Gr-1(RB6-8C5), CD11b(M1/70), H-2kb (AF6-88.5.5.3), GM-CSF (MP1-22E9), and the respective IgG isotype controls.

Intracellular staining and flow cytometry

Cells were stimulated with anti-CD3 and anti-CD28 mAbs for 3 d and restimulated with PMA and ionomycin for 5 h in the presence of brefeldin A before intracellular staining. Cells were fixed with IC Fixation Buffer (BD Biosciences), incubated with permeabilization buffer, and stained with PE anti-mouse, allophycocyanin anti-mouse, and FITC anti-mouse Abs. Flow cytometry was performed on a FACSCalibur (BD Biosciences) and LSR Fortessa (BD Biosciences).

FIGURE 2. Mice with IRF8 deficiency only in myeloid cells exhibit normal myelopoiesis. (A) Spleen morphology of 3-mo-old WT, IRF8 MKO, and IRF8 KO mice. (B) Percentages of CD11b+Gr1+ MDSCs in thymus (Thy), spleen (SP), lymph node (LN), and BM of WT and IRF8 MKO mice. Shown are representative results from one mouse of three mice. (C) Quantitation of CD11b+Gr1+ in SP and BM of WT (n = 3) and IRF8 MKO (n = 3) mice, as shown in (B). (D) Subsets of Gr1+ (Ly6C+ and Ly6G+) myeloid cells SP and BM. Shown are representative results from one mouse of three mice. Column, mean; bar, SD. (E) Quantification of subsets of Gr1+ myeloid cells in SP and BM of WT (n = 3) and IRF8MKO (n = 3) mice. (F) The indicated tissues were collected from WT and IRF8 MKO mice, stained with the CD4- and CD8-specific mAbs. Shown are representative images CD4+ and CD8+ T cell profiles. (G) Quantification of CD4+ and CD8+ T cells in the indicated tissues from WT (n = 3) and IRF8 MKO (n = 3) mice. Column, mean; bar, SD.

Intracellular staining and flow cytometry

Cells were stimulated with anti-CD3 and anti-CD28 mAbs for 3 d and restimulated with PMA and ionomycin for 5 h in the presence of brefeldin A before intracellular staining. Cells were fixed with IC Fixation Buffer (BD Biosciences), incubated with permeabilization buffer, and stained with PE anti-mouse, allophycocyanin anti-mouse, and FITC anti-mouse Abs. Flow cytometry was performed on a FACSCalibur (BD Biosciences) and LSR Fortessa (BD Biosciences).

T cell transfer models

T cell transfer was performed as previously described (Powrie et al. 1993). In brief, purified CD4+ T cells from wild-type (WT) and IRF8 KO mice were injected i.p. into Rag1 KO recipients (5 x 10⁶ cells per mouse in 200 µl sterile PBS per injection). Mice were weighed every week throughout the course of experiments. After 4 wk, mice were sacrificed; spleen, mesenteric lymph node, and BM were picked up for flow cytometer analysis.

IRF8 overexpression and GM-CSF expression in T cells

The retroviral vector (RV) used in this study was the MIG retroviral vector that consisted of a MSCV-IRES-GFP vector. Mouse naïve CD4+ T cells...
from C57BL/6 WT and IRF8 KO mouse spleens were transduced with empty RV control (RV-MIG) and the RV containing the IRF8 coding sequence (RV-MIG-IRF8), respectively. The cells were activated under anti-CD3 and anti-CD28 Abs for 3 d; then restimulated with PMA/ionomycin for 5 h; and stained for surface CD4 and intracellular GM-CSF. Total RNA was also isolated and analyzed for GM-CSF expression by real-time RT-PCR.

Acute graft-versus-host disease model

All donor BM cells were isolated from C57BL/6 (H-2 b) mice. T cell depletion of BM was performed with auto-MACS by using anti-CD90.2 microbeads (Miltenyi Biotec). Donor CD4+ T cells (purity ∼95%) were purified from the spleens of C57BL/6 or GM-CSF−/− mice (H-2 b) by using the CD4 beads (Miltenyi Biotec). The BALB/c (H-2 d) hosts were irradiated with 9 Gy from 137Cs source. One day later, the hosts were injected i.v. with 2 × 10^6 BM cells only or combined with 0.3 × 10^6 CD4+ T cells isolated from C57BL/6 or GM-CSF KO mice. The hosts were weighed every 2 d and monitored for survival. The H-2Kb+ myeloid cells were gated and analyzed for CD11b+Gr1+ cells by FACS in spleen and BM in host at 11 and 14 d after donor BM cell transfer.

Cytokine ELISA

Supernatants from cell cultures were collected after activation under various conditions, and secreted cytokines in the supernatants were measured by ELISA kits with purified coating and biotinylated detection Ab anti–GM-CSF (eBioscience).

RT-PCR analysis

Total RNA was isolated from cells using TRIzol (Invitrogen, San Diego, CA), according to the manufacturer’s instructions, and used for the first-strand cDNA synthesis using the Moloney murine leukemia virus reverse transcriptase (Promega). The cDNA was then used as template for semi-quantitative and real-time PCR analysis. The sequences of primers are listed in Supplemental Table I.

Chromatin immunoprecipitation

CD4+ T cells were isolated from spleens of WT mice using negative selection method (BioLegend) and stimulated with anti-CD3 and anti-CD8 mAbs for 3 d. Chromatin immunoprecipitation was performed using anti-IRF8 Ab (C19; Santa Cruz, Dallas, TX) and the protein A agarose, according to the manufacturer’s instructions (Millipore, Temecula, CA). Goat IgG was used as negative control for the Ab. The immunoprecipitated genomic DNA was amplified by real-time PCR using five pairs of PCR primers (Supplemental Table I) covering the region approximately from −4000 to +1000 relative to the csf2 transcription initiation site in the csf2 promoter region.

Results

A key phenotype of IRF8 null mice is deregulation of myeloid cell lineage differentiation

IRF8 is a transcription factor of the IRF family. Mice with a null mutation of IRF8 exhibit two prominent phenotypes (36). The first is enhanced susceptibility to virus infections associated with impaired IFN-γ production. The second is deregulated myeloid cell lineage differentiation, characterized by splenomegaly (Supplemental Fig. 1A) and massive accumulation of CD11b+Gr1+ MDSCs in BM and spleen (Supplemental Fig. 1B). Therefore, IRF8 is a key transcription factor for myeloid cell lineage differentiation and is essential for the proliferation and differentiation of hematopoietic progenitor cells into mature myeloid cells (36, 37).

Myeloid cell–specific IRF8 deficiency does not ablate myeloid cell lineage differentiation

As mentioned above, IRF8-deficient mice exhibit deregulated myeloid cell lineage differentiation, resulting in accumulation of MDSCs (Supplemental Fig. 1). In keeping with earlier studies (13,
19, 41, 42), this indicates that IRF8 functions in myeloid cells to regulate myeloid cell lineage differentiation. However, whether IRF8 expressed in myeloid cells regulates myeloid cell lineage differentiation is still a hypothesis to be tested. Therefore, we created mice with IRF8 deficiency only in myeloid cells by crossing mice with a loxp-flanked Irf8 gene [B6(Cg)-Irf8tm1.1Hm/J] (9, 40) with the Lyz2-cre mice [B6.129P2-Lyz2tm1(cre)Ifo/J] (Fig. 1A). Exon 2 of Irf8 in the B6(Cg)-Irf8tm1.1Hm/J mouse is flanked by loxp sites, and it has been shown that deletion of exon 2 leads to depletion of IRF8 protein in cre-expressing tissues (40). We selected Irf8loxp+/+ and Lyz2cre+/+ mice based on genotypes (termed IRF8 MKO) (Supplemental Fig. 2). To confirm that exon 2 is indeed deleted from these mice, we designed PCR primers that flank exon 2 of Irf8 mRNA. CD11b+, Gr1+, and CD11b+Gr1+ cells were sorted from WT and IRF8 MKO mice and treated with IFN-γ and LPS for 24 h. RT-PCR analysis of Irf8 mRNA indicated that exon 2 was indeed deleted from Irf8 mRNA in IRF8 MKO mice (Fig. 1B). To determine whether the myeloid cells in IRF8 MKO mice are functionally deficient, the expression levels of IRF8 target genes in these cells were analyzed. IRF8 is a transcription activator of IL12p40 and inducible NO synthase and is a transcriptional repressor of IFN-γ-inducible protein 10 and IP1α expression levels are higher in Gr1+ cells from IRF8 MKO mice as compared with those from WT mice (Fig. 1C). IL12p40 levels were also lower in CD11b+ and CD11b*Gr1+ cells in IRF8 MKO mice as compared with WT mice (Fig. 1C). Our data thus indicate that IRF8 is functionally deficient in these myeloid cells. Therefore, we have created mice with irf8 mutation and IRF8 functional deficiency only in myeloid cells.

Surprisingly, analyses of IRF8 MKO mice revealed that they do not develop the splenomegaly characteristic of IRF8 KO mice (Fig. 2A). No significant differences were observed in the percentages of CD11b+, Gr1+, and CD11b*Gr1+ cells sorted from WT and IRF8 MKO mice (Fig. 2B, 2C). In addition, the subsets of monocytic and granulocytic MDSCs (Ly6G+ and Ly6C+) also did not differ significantly between WT and IRF8 MKO cells (Fig. 2D, 2E). There were no significant differences between these mice in the percentages of CD4+ and CD8+ T cells (Fig. 2F, 2G). These data thus indicate that IRF8 expressed in myeloid cells is not sufficient enough to mediate CD11b*Gr1+ MDSC differentiation.

IRF8 deficiency results in decreased spontaneous apoptosis in vivo

The above observation is a surprising one because IRF8-deficient myeloid cells from IRF8 MKO mice are functionally deficient (Fig. 1C) and IRF8 conventional KO mice exhibit deregulated myeloid cell lineage differentiation and resultant MDSC accumulation (36) (Supplemental Fig. 1). Therefore, we further func-
tionally examined these IRF8 MKO mice. Like T cells, myeloid cell turnover is mediated by the Fas–Fas ligand apoptosis pathway (45). It has been shown that IRF8 regulates the expression of multiple apoptosis-regulatory genes, including Bcl-XL, Bax, FLIP, and Fas, in myeloid cells (46–49), to regulate apoptosis (50, 51). Based on these observations, we then hypothesized that IRF8 deficiency at least should lead to decreased spontaneous apoptosis of MDSCs in IRF8 MKO mice. To test this hypothesis, we examined spontaneous apoptosis of MDSCs in WT and IRF8 MKO mice with IRF8 KO mice as positive controls. As expected, MDSCs from spleens and BM of IRF8 KO mice exhibited significantly reduced spontaneous apoptosis as compared with those from WT mice (Fig. 3A). Similar to what was observed in IRF8 KO mice, MDSCs from both spleens and BM of IRF8 MKO mice also exhibit significantly decreased spontaneous apoptosis (Fig. 3B). We should point out in this work that MDSCs from IRF8 KO and IRF8 MKO mice are all sensitive to apoptosis; only the level of spontaneous apoptosis in MDSCs of IRF8-deficient mice decreased as compared with the respective control WT mice. Therefore, we conclude that IRF8 deficiency leads to decreased MDSC spontaneous apoptosis. However, this deficiency alone apparently is not sufficient enough to cause MDSC accumulation.

**IRF8 deficiency in T cells leads to increased MDSCs**

Based on the above observations, we hypothesized that IRF8 expressed in other type(s) of cells plays a role in myeloid cell differentiation. To test this hypothesis, we analyzed mice with IRF8 deficiency only in T cells (termed IRF8 TKO) (39). In IRF8 TKO mice, cre expression is controlled by lck promoter that drives T cell–specific cre expression. IRF8 TKO mice have enlarged spleens as compared with WT mice (Fig. 4A). The percentages of CD11b+Gr1+ cells (Fig. 4B) in spleen, BM, and blood, and Ly6C+Ly6G− (Fig. 4D, 4E) cells in spleen and BM were significantly higher in IRF8 TKO mice as compared with WT mice.

Next, we took a complementary approach to determine the role of IRF8 expressed in T cells in regulation of MDSC differentiation. We purified CD4+ T cells from WT and IRF8 TKO mice and adoptively transferred these T cells to Rag1 KO mice. The rationale is that if IRF8 deficiency in T cells regulates myeloid cell lineage differentiation, then T cells from IRF8 KO mice should increase MDSC accumulation in the Rag1 KO recipients. Indeed, adoptive transfer of IRF8-deficient T cells to Rag1 KO mice resulted in increased spleen size and spleen cell number (Fig. 5A). Analysis of CD11b+Gr1+ cells indicated that adoptive transfer of IRF8-deficient T cells significantly increased CD11b+Gr1+ MDSC accumulation in the Rag1 KO mouse spleens (Fig. 5B). Taken together, our data indicate that IRF8 expressed in T cells mediates CD11b+Gr1+ MDSC lineage differentiation in vivo.

**IRF8 represses GM-CSF expression in T cells to regulate myeloid cell differentiation**

It is well documented that proinflammatory cytokines mediate CD11b+Gr1+ immature myeloid cell differentiation under pathological conditions (52–54). In particular, GM-CSF has been shown to induce CD11b+Gr1+ MDSC accumulation in tumor-bearing mice (53, 55–57). Recent studies have shown that tumor-secreted GM-CSF induces differentiation of MDSCs that phenotypically and functionally resemble tumor-induced MDSCs (55–57). Based on these observations, we hypothesized that IRF8 represses GM-CSF expression and IRF8 deficiency in T cells results in increased GM-CSF expression to induce deregulated myeloid cell differentiation. To test this hypothesis, we first cultured BM cells from WT mice in the presence of GM-CSF. Indeed, GM-CSF induced CD11b+Gr1+ cell differentiation from BM cells ex vivo (Fig. 6A). Next, purified CD4+ T cells from WT and IRF8 KO mice were cultured in the presence of anti-CD3 and anti-CD28 mAbs. Analysis of intracellular GM-CSF protein levels using flow cytometry revealed that GM-CSF is higher in T cells from IRF8 KO mice as compared with T cells from WT mice (Fig. 6B). Real-time RT-PCR analysis determined that GM-CSF transcript levels were also significantly higher in T cells from IRF8 KO mice than WT mice (Fig. 6C). Analysis of GM-CSF protein level in cell culture medium indicated that IRF8-deficient T cells secrete significantly more GM-CSF than WT T cells (Fig. 6C). Taken together, these observations indicate that IRF8 functions as a repressor of GM-CSF in T cells.

**T cell–produced GM-CSF promotes MDSC differentiation**

To functionally determine the role of GM-CSF in myeloid cell differentiation in vivo, rGM-CSF protein was injected into WT mice. Analysis of GM-CSF–treated mice revealed that CD11b+Gr1+ MDSC increased significantly in blood, spleen, and BM (Fig. 6D, 6E). To further determine that activated T cells can enhance myeloid cell development in vivo, we then made use of an acute graft-versus-host disease model to determine the function of T cell–produced GM-CSF in myeloid cell differentiation. BALB/c (H-2b) recipient mice were irradiated. T cell–depleted BM cells were prepared from C57BL/6 mice (H-2Kb). CD4+ T cells were purified from WT, IRF8 KO, and GM-CSF KO mice (C57BL/6, H-2Kb). BM alone or BM in combination with the purified T cells was then adoptively transferred to the recipient mice. In this graft-versus-host disease model, transferred T cells could be activated by three ways, as follows: 1) direct Ag pre-
FIGURE 6. IRF8 represses GM-CSF expression in T cells to suppress MDSC accumulation. (A) GM-CSF induces BM cell differentiation to CD11b+Gr1+ MDSCs. BM cells were prepared (left panel) and cultured in vitro in the presence of GM-CSF for 4 d (right panel) and analyzed for CD11b+ and Gr1+ cells. (B) Purified CD4+ T cells from WT and IRF8 KO mice were stimulated with anti-CD3 and anti-CD28 mAbs for 3 d. Cells were stained intracellularly with GM-CSF–specific mAb and analyzed by flow cytometry. (C) Left panel, CD4+ T cells were purified from spleens of WT and IRF8 KO mice and stimulated with anti-CD3 and anti-CD28 mAbs for 3 d. RNAs were prepared and analyzed by real-time RT-PCR for GM-CSF mRNA level using β-actin as internal control. Right panels, CD4+ T cells were purified from spleens of WT, IRF8 KO, and IRF8 TKO mice and stimulated with anti-CD3 and anti-CD28 mAbs for 3 d. The culture supernatants were analyzed by ELISA for GM-CSF protein level. Column, mean; bar, SD. **p < 0.01. (D) WT mice were injected i.p. with rGM-CSF protein (1 μg in 100 μl PBS per mouse) every 2 d three times. Myeloid cells in the indicated tissues were analyzed by flow cytometry. Shown are representative results from one mouse of three mice. (E) Quantification of CD11b+Gr1+ cells, as shown in (D). Column, mean; bar, SD. **p < 0.01.

Discussion

The mammalian immune system consists of an innate and an adaptive component. The innate immune system that comprises primarily myeloid cells uses a limited number of germline-encoded pattern–recognition receptors to detect the relatively invariant pathogen-associated molecular patterns (58). In contrast, the adaptive immune system, which is composed of T and B cells, employs Ag receptors that are not encoded in the germline but are generated de novo. Although the adaptive immune system depends on the generation of almost unlimited repertoire of Ag

sentation by donor APCs; 2) indirect Ag presentation by recipient APCs (cross presenting); and 3) MLR. The rationale is that if IRF8 is a repressor of GM-CSF and activated T cell–produced GM-CSF promotes CD11b+Gr1+ cell differentiation, then more H-2Kb+CD11b+Gr1+ cells should accumulate in the recipient H-2d mice. Analysis of the chimeric mice indicated that adoptive transfer of T cells increased spleen size and spleen cell number as compared with BM-only transfer. However, both spleen sizes and number of spleen cells were greater in the recipient H-2d mice that received IRF8 KO T cells and BM as compared with recipients of WT T cells and BM (Fig. 7A). Furthermore, T cells from GM-CSF KO mice did not induce increased spleen sizes and spleen cell numbers (Fig. 7A).

Consistent with the increased spleen sizes and spleen cell numbers, the percentages of donor H-2Kb+CD11b+Gr1+ cells were higher in the recipient H-2d mice receiving IRF8 KO T cells than those receiving WT T cells. In contrast, mice receiving GM-CSF KO T cells exhibited no differences in H-2Kb+CD11b+Gr1+ cells as compared with control mice (Fig. 7B, 7C).

A complementary approach was then used to further determine the function of IRF8 in repression of GM-CSF expression. Naive CD4+ T cells from C57BL/6 WT and IRF8 KO mice were transduced with retroviral vector encoding IRF8 or empty vector, and were activated with anti-CD3 and anti-CD28 Abs. The cells were restimulated with PMA/ionomycin for 5 h and stained for surface CD4 and intracellular GM-CSF. It is apparent that overexpression of IRF8 significantly decreases the percentage of GM-CSF–expressing cells in both WT and IRF8 KO CD4+ T cells (Fig. 8A, 8B). Analysis of GM-CSF mRNA level indicates that overexpression of IRF8 significantly decreased GM-CSF mRNA level (Fig. 8C).

To determine whether IRF8 also regulates GM-CSF expression in MDSCs, MDSCs were purified from spleen cells of WT and IRF8 KO mice. Total RNA was isolated from the purified MDSCs and analyzed for GM-CSF mRNA expression by real-time RT-PCR. It is clear that, unlike in T cells, IRF8 deficiency in MDSCs clearly does not increase GM-CSF expression in MDSCs (Fig. 9). Taken together, our data demonstrate that IRF8 expressed in T cells functions as a GM-CSF repressor to control myeloid cell lineage differentiation, and IRF8 deficiency in T cells leads to increased GM-CSF expression to deregulate myeloid cell cell lineage differentiation and resultant MDSC accumulation.

In summary, we determined that, under physiological conditions, IRF8 expressed in T cells represses GM-CSF expression to control myeloid cell lineage differentiation, whereas IRF8 expressed in myeloid cells mediates myeloid cell spontaneous apoptosis to regulate myeloid cell turnover. Loss of IRF8 function in T cells leads to increased GM-CSF expression to induce deregulated myeloid cell differentiation, which acts in concert with loss of IRF8 function in myeloid cell and resultant decreased spontaneous apoptosis to result in MDSC accumulation (Fig. 10).

Discussion

The mammalian immune system consists of an innate and an adaptive component. The innate immune system that comprises primarily myeloid cells uses a limited number of germline-encoded pattern–recognition receptors to detect the relatively invariant pathogen-associated molecular patterns (58). In contrast, the adaptive immune system, which is composed of T and B cells, employs Ag receptors that are not encoded in the germline but are generated de novo. Although the adaptive immune system depends on the generation of almost unlimited repertoire of Ag
receptors on T and B cells and subsequent activation and clonal expansion of T and B cells carrying the Ag-specific receptors, the innate immune system is the first line of defense that recognizes the pathogen-associated molecular patterns to deliver essential danger signals to activate the adaptive immune system (29). Thus, the innate immune cells, primarily the myeloid cells, regulate the

![Image](https://example.com/image.png)

**FIGURE 7.** T cell–produced GM-CSF induces MDSC differentiation. (A) BALB/c mice (H-2d) were irradiated with 9 Gy from a 137Cs source and were injected i.v. with 2 × 10^6 T cell–depleted BM cells alone, or combined with 0.3 × 10^6 CD4+ T cells isolated from C57BL/6 (H-2k), C57BL/6-IRF8 KO, C57BL/6-GM-CSF KO mice. Mice were analyzed 14 d after cell transfer. Spleens of the indicated chimera mice are shown. Spleen cell numbers are presented in the right panel. (B) The H-2k+CD11b+ and H-2kb+Gr1+ myeloid cells in the indicated chimera mice were analyzed by flow cytometry in spleens 11 d after donor cell transfer. Shown are representative results from one mouse of three mice. (C) Quantification of CD11b+ and Gr1+ cells in the indicated mice as shown in (B). Column, mean; bar, SD. **p < 0.01.

**FIGURE 8.** Restoration of IRF8 expression decreases GM-CSF+ T cells. Naive CD4+ T cells from C57BL/6 WT and IRF8−/− mice were transduced with retrovirus encoding IRF8 or empty vector, and the cells were activated with anti-CD3 and anti-CD28 Abs for 3 d. The cells were restimulated with PMA/ionomycin for 5 h, stained for intracellular GM-CSF, and analyzed by flow cytometry. Representative FACS dot plots gated on CD4+ T cells and the percentage of GM-CSF–producing CD4+ T cells are shown. (A) Column, mean; bar, SD. Overexpression of IRF8 significantly decreased percentage of GM-CSF+ cells in both WT and IRF8 KO CD4+ T cells (***p < 0.01). (C) Total RNA was prepared from cells, as shown in (A), and analyzed for GM-CSF mRNA levels by real-time RT-PCR using β-actin as internal control. Overexpression of IRF8 significantly decreased GM-CSF mRNA levels in both WT and IRF8 KO CD4+ T cells (***p < 0.01).
The Journal of Immunology

FIGURE 9. GM-CSF is not downregulated in MDSCs from IRF8 KO mice. CD11b+Gr1+ MDSCs were purified from spleens of WT (n = 4) and IRF8 KO (n = 3) mice. Total RNA was isolated from these purified MDSCs and analyzed for IRF8 expression levels by real-time RT-PCR using β-actin as the internal control. The expression levels of IRF8 in MDSCs from the first WT mice were arbitrarily set at 1.0. The expression levels of IRF8 in MDSCs of the rest samples were the levels relative to the IRF8 expression level in MDSCs of first WT mice.

adaptive immune response under pathophysiological conditions (4, 29, 59–61). In this study, we show that T cells regulate myeloid cell differentiation through an IRF8-mediated and GM-CSF–dependent extrinsic mechanism in vivo. Our findings therefore revealed that the adaptive immune component of the immune system (i.e., T cells) regulates the innate myeloid cell lineage differentiation.

Decades ago, a seminal study with Irf8−/− mice revealed IRF8 as an essential transcription factor in regulating myeloid cell lineage differentiation (36). One of the prominent phenotypes of IRF8 null mice is the massive accumulation of CD11b+Gr1+ cells in BM, spleen, blood, and peripheral lymphoid organs as a consequence of differentiation (36). One of the prominent phenotypes of IRF8 null mice is the massive accumulation of CD11b+Gr1+ cells in BM, spleen, blood, and peripheral lymphoid organs as a consequence of differentiation (36). Interestingly, pathological conditions, that is, cancer, also induce massive accumulation of CD11b+Gr1+ cells termed MDSCs (CD11b+Gr1+ in mice and CD11b+CD33+ in humans) (62–64). Furthermore, glioblastoma multiforme and pancreatic cancer cells have been shown to secrete GM-CSF to induce tumor-associated macrophage and MDSC accumulation in the tumor-bearing host (55, 57, 65). Moreover, IRF8 expression is often silenced in CD11b+Gr1+ MDSCs in the tumor-bearing hosts (38, 49). These observations clearly demonstrate an inverse correlation between IRF8 expression/function and CD11b+Gr1+ MDSC accumulation under both physiological and pathological conditions. These observations thus suggest that IRF8 functions in myeloid cells mediate myeloid cell differentiation and loss of IRF8 expression or function causes deregulation of myelopoiesis and resultant MDSC accumulation. However, our present data strongly support a model showing that myeloid IRF8 levels can also be controlled extrinsically to regulate myeloid cell differentiation and MDSC accumulation in vivo. In this study, we showed that IRF8 expression in T cells is critical for the production of GM-CSF which, in turn, impacts IRF8 expression levels in the receptive myeloid populations and the resultant myeloid phenotype. The relationship between IRF8 expression and GM-CSF production in tumor cells warrants further study, as well as detailing IRF8 expression levels in the different myeloid progenitor populations of the IRF8 MKO model.

A previous study has convincingly demonstrated that mixed BM chimeras generated from a mixture of WT and IRF8 KO BM display defects only in myeloid cells differentiated from the IRF8 KO BM, indicating a myeloid cell–intrinsic abnormality in IRF8-deficient myeloid progenitors (31). In this study, we observed IRF8 intrinsic function in myeloid cells in apoptosis regulation. However, it seems that the extrinsic function of IRF8 as a regulator of GM-CSF expression plays a more dominant role in MDSC accumulation under our conditions. It is clear that IRF8 clearly represses GM-CSF expression in T cells. Analysis of the csf2 promoter region revealed two putative IFN-stimulated response element sites (Supplemental Fig. 3A); however, our initial attempts have failed to detect direct IRF8 binding to the csf2 gene promoter (Supplemental Fig. 3B), suggesting that IRF8 may regulate GM-CSF expression through an indirect mechanism. Further studies are needed to determine the mechanisms underlying csf2 transcription regulation by IRF8.

The lyz2 promoter used in generating the IRF8 MKO mice is the most commonly used one for myeloid cell–specific gene expression in the literature (66–70). The current expressed sequence tag data indicate that the expression level of lysozyme 2 is highest in BM as compared with other tissues in mice (http://www.ncbi.nlm.nih.gov/UniGene/ESTProfileViewer.cgi?uglist=Mm.45436). Therefore, it is unlikely that lyz2 promoter is not activated in BM. In the literature, it is well demonstrated that lyz2-driven Cre expression induces specific and highly efficient deletion of loxp-flanked gene segments in mature myeloid cells (66–69). However, it was also observed that lyz2-driven Cre-mediated deletion of loxp-flanked gene segments is less efficient in immature myeloid cells as compared with that in mature amyloid cells (66–68). Therefore, it is possible that IRF8 is only partially deleted in myeloid progenitor cells. In contrast, IRF8 expression...
level in hematopoietic stem cells is negligible, but increases with differentiation of hematopoietic stem cells into immature myeloid cells. Differentiation of hematopoietic stem cells into the multi-potent progenitor→common lymphoid progenitor→granulocyte-myeloid progenitor pathway coincided with sequential increases in IRF8 expression (9). This IRF8 expression pattern correlates at least partially with β2 promoter activity and lysozyme 2 expression patterns during myeloid cell lineage differentiation. It is apparent that further studies are warranted to determine the β2 promoter activity and IRF8 deletion during myeloid cell lineage differentiation in the IRF8 KO mice.

Although IRF8 expressed in myeloid cells is not sufficient enough to intrinsically regulate myeloid cell differentiation, the fact that IRF8 is often silenced in MDSCs in tumor-bearing mice and human cancer patients suggests that IRF8 expressed in myeloid cells should play a role in MDSC accumulation (38, 49, 71). IRF8 is a transcription factor previously shown to regulate the expression of multiple apoptosis-regulatory genes, including Bcl-2, Bax, FLIP, and Fas, in myeloid cells (46–49). Furthermore, as in T cells, it has been shown that MDSC turnover is mediated by the Fas–Fas ligand apoptosis pathway of the host’s immune cells (45). It is well known that deregulation of Fas-mediated apoptosis in T cells leads to autoimmune lymphoproliferative syndrome with massive T cell accumulation (72), which resembles massive MDSC accumulation in IRF8 null mice. Therefore, by parallel, it is reasonable to assume that IRF8 deficiency-induced deregulation of the Fas-mediated apoptosis pathway in MDSCs might decrease MDSC sensitivity to host immune cell-mediated apoptosis. Indeed, MDSCs from IRF8 KO mice exhibit decreased spontaneous apoptosis. MDSCs from IRF8 KO mice also exhibit decreased spontaneous apoptosis. Therefore, in addition to regulating MDSC differentiation in an extrinsic manner, IRF8 also mediates MDSC spontaneous apoptosis to control their turnover. Thus, increased differentiation induced by T cell–produced GM-CSF, acting in concert with decreased MDSC spontaneous apoptosis/turnover, leads to MDSC accumulation in IRF8-deficient host.

The molecular mechanism underlying MDSC accumulation has been subject of extensive studies (38, 46, 73). In this study, we observed that IRF8 functions extrinsically as a GM-CSF repressor in T cells. We show that IRF8-deficient T cells express elevated level of GM-CSF. Based on our observations, we propose that IRF8 is a GM-CSF repressor. Loss of IRF8 function in T cells results in increased GM-CSF expression and secretion. GM-CSF binds to its receptor on myeloid progenitor cells to increase MDSC differentiation. At the same time, loss of IRF8 function in the differentiating myeloid cells decreases their spontaneous apoptosis and turnover. GM-CSF–induced increase in MDSC differentiation, in concert with IRF8 deficiency–mediated decrease in MDSC turnover, causes massive MDSC accumulation (Fig. 10).

Acknowledgments
We thank Dr. Jeanene Pihkala in the Medical College of Georgia Flow Cytometry Core Facility for the excellent technical assistance in cell sorting.

Disclosures
The authors have no financial conflicts of interest.

References